Treatment for myelodysplastic syndrome by hypomethylating agents may activate an oncogene
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS), and increasingly in other diseases, but their mechanism of action is not clear. HMAs may affect many ...
May 26, 2022
0
18